Skip to content

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Aug 2026

Danburstotug, an anti-PD-L1 antibody, in relapsed/refractory extra-nodal natural killer/T-cell lymphoma: The phase 2 DISTINKT study.

Relapsed/refractory extra-nodal natural killer/T-cell lymphoma (R/R ENKTL) has limited treatment options. Danburstotug, an antibody targeting programmed death-ligand 1 (PD-L1), was evaluated in adults with R/R ENKTL in a phase 2, open-label study (NCT04414163). Danburstotug 20 mg/kg was administered intravenously every...

W. Kim, S. Kim, Jae-Cheol Jo et al. · 0 citations
Sep 2026

Protocol and Cohort Profile of a Prospective Multicenter Lymphoma Cohort in South Korea.

BACKGROUND Real-world data are increasingly used to support pragmatic clinical trials. However, most existing oncology cohorts lack high-frequency symptom data and standardized infrastructures required for longitudinal outcome assessment. OBJECTIVE To describe the design of a prospective multicenter lymphoma cohort i...

D. Kang, Kunye Kwak, Ka-Won Kang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.